The Capital Behind Vision Restoration

Science Corp. closed a $230 million funding round at a $1.25 billion valuation, according to a source familiar with the matter. The raise brings the neurotechnology company’s total capital to $489 million as it advances toward commercial launch of its retinal implant designed to restore vision in people with certain forms of blindness.

The company, founded by Max Hodak after his departure from Neuralink, has built its approach around a fundamentally different problem than most BCI startups chasing computer control or paralysis treatment. Restoring sight through neural interfaces requires solving both the hardware challenge of biocompatible implants and the software problem of translating visual information into signals the brain can interpret. Science Corp.’s device bypasses damaged photoreceptors in the retina, directly stimulating remaining healthy cells to create visual perception.

Why This Round Matters

The valuation signals investor confidence in a specific application of neural interface technology rather than the broader, more speculative promises that have defined much of the BCI funding landscape. Blindness affects an estimated 2.2 billion people globally, with degenerative conditions like retinitis pigmentosa and age-related macular degeneration representing tractable targets for intervention. The market opportunity is both massive and more clearly defined than general-purpose brain-computer interfaces.

Science Corp. has already demonstrated its technology in early human trials, a milestone that separates companies with functioning prototypes from those still working through basic feasibility questions. Moving from clinical validation to commercial availability requires manufacturing scale, regulatory navigation, and distribution infrastructure. This funding round appears designed to support exactly that transition.

The timing also reflects a maturing understanding among investors about which neural interface applications will reach patients first. While companies like Neuralink capture headlines with ambitious long-term visions, sensory restoration through targeted implants presents fewer technical hurdles and clearer regulatory pathways. Science Corp.’s ability to command a unicorn valuation suggests capital is flowing toward near-term medical solutions rather than speculative moonshots. The question now becomes whether the company can convert clinical promise into a scalable commercial product that justifies the expectations embedded in this valuation.